Insider Transactions in Q3 2024 at Artiva Biotherapeutics, Inc. (RTVA)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+40.72%
|
-
|
|
Sep 12
2024
|
Neha Krishnamohan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Sep 12
2024
|
Christopher Horan Chief Tech Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Sep 12
2024
|
Thorsten Graef Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Sep 12
2024
|
Heather Raymon SVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
8,333,333
+46.11%
|
$99,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+36.78%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,058,282
+50.0%
|
-
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Open market or private purchase
|
Indirect |
833,333
+41.35%
|
$9,999,996
$12.0 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Other acquisition or disposition
|
Indirect |
461,687
+29.4%
|
$4,616,870
$10.2 P/Share
|
|
Jul 22
2024
|
5 Am Partners Vi, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,058,284
+50.0%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Indirect |
416,666
+24.84%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Indirect |
256,316
+23.3%
|
$2,563,160
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Indirect |
354,972
+22.68%
|
-
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Open market or private purchase
|
Direct |
1,666,666
+33.51%
|
$19,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Other acquisition or disposition
|
Direct |
294,117
+15.2%
|
$2,941,170
$10.2 P/Share
|
|
Jul 22
2024
|
Gc Corp. |
BUY
Conversion of derivative security
|
Direct |
997,280
+29.67%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Open market or private purchase
|
Direct |
416,666
+17.71%
|
$4,999,992
$12.0 P/Share
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Other acquisition or disposition
|
Direct |
461,687
+23.3%
|
-
|
|
Jul 22
2024
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Conversion of derivative security
|
Direct |
1,058,284
+33.43%
|
-
|
|
Jul 22
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Other acquisition or disposition
|
Direct |
49,019
+20.16%
|
$490,190
$10.2 P/Share
|
|
Jul 22
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Conversion of derivative security
|
Direct |
145,089
+50.0%
|
-
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Open market or private purchase
|
Indirect |
2,083,332
+29.18%
|
$24,999,984
$12.0 P/Share
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Other acquisition or disposition
|
Indirect |
550,433
+19.25%
|
$5,504,330
$10.2 P/Share
|
|
Jul 22
2024
|
Yong Jun Huh |
BUY
Conversion of derivative security
|
Indirect |
1,352,252
+26.17%
|
-
|
|
Jul 22
2024
|
Fred Aslan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
228,905
+50.0%
|
-
|